Literature DB >> 24954365

Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment.

Karim J Halazun1, Rachel E Patzer, Abbas A Rana, Elizabeth C Verna, Adam D Griesemer, Ronald F Parsons, Benjamin Samstein, James V Guarrera, Tomoaki Kato, Robert S Brown, Jean C Emond.   

Abstract

UNLABELLED: Priority is given to patients with hepatocellular carcinoma (HCC) to receive liver transplants, potentially causing significant regional disparities in organ access and possibly outcomes in this population. Our aim was to assess these disparities by comparing outcomes in long waiting time regions (LWTR, regions 5 and 9) and short waiting time regions (SWTR regions 3 and 10) by analyzing the United Network for Organ Sharing (UNOS) database. We analyzed 6,160 HCC patients who received exception points in regions 3, 5, 9, and 10 from 2002 to 2012. Data from regions 5 and 9 were combined and compared to data from regions 3 and 10. Survival was studied in three patient cohorts: an intent-to-treat cohort, a posttransplant cohort, and a cohort examining overall survival in transplanted patients only (survival from listing to last posttransplant follow-up). Multivariate analysis and log-rank testing were used to analyze the data. Median time on the list in the LWTR was 7.6 months compared to 1.6 months for SWTR, with a significantly higher incidence of death on the waiting list in LWTR than in SWTR (8.4% versus 1.6%, P < 0.0001). Patients in the LWTR were more likely to receive loco-regional therapy, to have T3 tumors at listing, and to receive expanded-criteria donor (ECD) or donation after cardiac death (DCD) grafts than patients in the SWTR (P < 0.0001 for all). Survival was significantly better in the LWTR compared to the SWTR in all three cohorts (P < 0.0001 for all three survival points). Being listed/transplanted in an SWTR was an independent predictor of poor patient survival on multivariate analysis (P < 0.0001, hazard ratio = 1.545, 95% confidence interval 1.375-1.736).
CONCLUSION: This study provides evidence that expediting patients with HCC to transplant at too fast a rate may adversely affect patient outcomes.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24954365     DOI: 10.1002/hep.27272

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

Review 1.  New Paradigm: Adaptive Approach.

Authors:  Hikmet Akkız
Journal:  J Gastrointest Cancer       Date:  2017-09

2.  Pathway of care of hepatocellular carcinoma in 2017.

Authors:  Federica Invernizzi; Massimo Colombo
Journal:  Hepat Oncol       Date:  2017-06-21

Review 3.  Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.

Authors:  Nicole E Rich; Neehar D Parikh; Amit G Singal
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

Review 4.  When to consider liver transplantation in hepatocellular carcinoma patients?

Authors:  Ka Wing Ma; Tan To Cheung
Journal:  Hepat Oncol       Date:  2017-07-06

5.  Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.

Authors:  Neil Mehta; Jennifer Guy; Catherine T Frenette; Jennifer L Dodge; Robert W Osorio; William B Minteer; John P Roberts; Francis Y Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2017-11-23       Impact factor: 11.382

Review 6.  Hepatocellular carcinoma: when is liver transplantation oncologically futile?

Authors:  André Viveiros; Heinz Zoller; Armin Finkenstedt
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-24

7.  Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Hepatology       Date:  2019-02-10       Impact factor: 17.425

8.  Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".

Authors:  Neil Mehta; Julie Heimbach; David Lee; Jennifer L Dodge; Denise Harnois; Justin Burns; William Sanchez; John P Roberts; Francis Y Yao
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

Review 9.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

10.  Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Clin Transplant       Date:  2017-10-15       Impact factor: 2.863

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.